Skip to main content
Log in

Comparative bioavailability of two different rectal preparations of piroxicam in man

  • Short Communications
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

A comparative pharmacokinetic study was performed with two types of suppository each containing 20 mg piroxicam. The bioavailability of piroxicam was studied in 24 healthy volunteers in a double blind, randomised, cross over study.

No significant difference was found in the pharmacokinetic parameters [AUC(0–72 h), AUC, Cmax, t1/2β calculated from plasma concentration time curves, indicating that the two preparations were bioequivalent.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Lombardino JG, Wiseman EH, Chiaini I (1973) Potent antiinflammatory N-heterocyclic 3-carboxamides of 4-hydroxy-2-methyl-2H-1,2-benzothiazine 1,1-dioxide. J Med Chem 16: 493–496

    Article  CAS  PubMed  Google Scholar 

  2. Wiseman EH, Chang YH, Lombardino JG (1976) Piroxicam, a novel anti-inflammatory agent. Arzneim/Forsch 26: 1300–1303

    CAS  Google Scholar 

  3. Otterness IG, Wiseman EH, Gans DJ (1977) Piroxicam. Agents Actions 9: 177–182

    Google Scholar 

  4. Brogden RN, Pinder RM, Speight TM (1977) Piroxicam; a review of its pharmacological properties and therapeutic efficacy. Drugs 22: 165–187

    Google Scholar 

  5. Hobbs DC (1983) Pharmacokinetics of piroxicam in man. Eur J Rheum Inflam 6: 46–55

    CAS  Google Scholar 

  6. Schiantarelli P, Acerbi D, Bovis G (1981) Some pharmacokinetic properties and bioavailability by oral and rectal route of piroxicam and rodents and in man. Arzneim Forsch 31: 92–98

    CAS  Google Scholar 

  7. Skreblin M, Alebic-Kolbah T, Hofman H (1987) Piroxicam bioavailability by rectal application of Felden and Luber, and oral application of Lubor. Acta Pharm Jugosl 37: 361–369

    CAS  Google Scholar 

  8. Hobbs DC, Twomey TM (1979) Piroxicam pharmacokinetics in man: aspirin and antacid interaction studies. J Clin Pharmacol 19: 270–281

    CAS  PubMed  Google Scholar 

  9. Macek J, Vacha J (1987) Rapid and sensitive method for determination of piroxicam in human plasma by high-performance liquid chromatography. J Chromatogr 420: 445–449

    CAS  PubMed  Google Scholar 

  10. Acerbi D, Dacco L, Palummeri E (1983) Pharmacokinetic study of piroxicam after p. o. and rectal administration. Boll Chim Farm 122 [Suppl] 19–27

    Google Scholar 

  11. Ishizaki T, Nomura T, Abe T (1979) Pharmacokinetics of piroxicam, a new nonsteroidal, anti-inflammatory agent, under fasting and postprandial states in man. J Pharmacokinet Biopharm 7: 369–381

    Article  CAS  PubMed  Google Scholar 

  12. Rogers HJ, Savitshy IP, Glenn B (1981) Kinetics of single doses of fenbufen in patients with renal sufficience. Clin Pharmacol Ther 29: 74–80

    CAS  PubMed  Google Scholar 

  13. Brogden RN, Heel RC, Speight TM, Avery GS (1981) Fenbufen: a review of its pharmacological properties and therapeutic use in rheumatic diseases and acute pain. Drugs 21: 1–22

    CAS  PubMed  Google Scholar 

  14. Lombardino JG, Wiseman EH, Otterness IG (1975) Acidic antiinflammatory agents -correlations of some physical, pharmacological and clinical data. Arzneim Forsch 25: 1629–1634

    CAS  Google Scholar 

  15. Twomey TM, Hobbs DC (1978) Biotransformation of piroxicam by man. Fed Proc 37: 271–275

    Google Scholar 

  16. Twomey TM, Bartolucci SE, Hobbs DC (1980) Analysis of piroxicam in plasma by high-performance liquid chromatography. J Chromatogr 183: 104–108

    CAS  PubMed  Google Scholar 

  17. Benkő-Márkus S, Grézal Gy, Nagy É, Klebovich I (1991) Comparative pharmacokinetic and bioequivalence studies. (in Hungarian) Gyógyszerészet 35: 479–481

    Google Scholar 

  18. Schuirmann DJ (1987) A comparison of the two one-sided test procedure and the power approach for assesing the equivalence of average bioavailability. J Pharmacokinet Biopharm 15: 657–680

    Article  CAS  PubMed  Google Scholar 

  19. Westlake WJ (1976) Symmetrical confidence intervals for bioequivalence trials. Biometrics 32: 741–744

    CAS  PubMed  Google Scholar 

  20. Westlake WJ (1978) Table to facilitate determination of symmetrical confidence intervals in bioavailability trials with Westlake's method. Eur J Drug Metab Pharmacokinet 2: 129–132

    Google Scholar 

  21. Hauck WW, Anderson S (1984) A new statistical procedure for testing equivalence in two-group comparative bioavailability trials. J Pharmacokinet Biopharm 12: 83–91

    CAS  PubMed  Google Scholar 

  22. Svåb J (1981) Biometrical methods in the research. Mezőgazdasági Kiadó, Budapest (in Hungarian)

    Google Scholar 

  23. Pabst G, Jaeger H (1990) Review of methods and criteria for evaluation of bioequivalence studies. Eur J Clin Pharmacol 38: 5–10

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Benkö, S., Grézal, G., Nagy, É. et al. Comparative bioavailability of two different rectal preparations of piroxicam in man. Eur J Clin Pharmacol 43, 315–317 (1992). https://doi.org/10.1007/BF02333031

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02333031

Key words

Navigation